ClinicalTrials.gg
Not yet recruitingNCT06628778Updated May 26, 2026

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

A Phase 3 interventional study of Enoxaparin in Venous Thromboembolism (VTE), sponsored by Johns Hopkins All Children's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Johns Hopkins All Children's Hospital · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
802
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing enoxaparin in Venous Thromboembolism — 5 open to participants now, 5 under way, 2 of them phase 3. Enoxaparin · Venous Thromboembolism.

Planned enrollment
7th of 32
802 · median 123
Started
2027
the only one that year
Phase 3
8 of 32
1 open now
Registered
30th of 32
by date

Among the 32 studies testing enoxaparin in Venous Thromboembolism, this one is the 7th largest by planned enrollment, is the only one that started in 2027, is one of 8 in phase 3, and was the 30th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

5 of the 32 studies testing enoxaparin in Venous Thromboembolism are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About enoxaparin

Enoxaparin: first FDA approval 1993 (LOVENOX (PRESERVATIVE FREE)), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing enoxaparin in Venous Thromboembolism, or all of them as a file.
02

Study summary

Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin enoxaparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.

Read the detailed description

This trial will establish definitive evidence on the comparative efficacy and safety of pharmacological thromboprophylaxis with the low molecular weight heparin (LMWH) enoxaparin versus no pharmacological thromboprophylaxis for the primary prevention of venous thromboembolism (VTE), including deep vein thrombosis and/or pulmonary embolism) among critically ill adolescents who meet a priori criteria for high risk of hospital-acquired (HA-) VTE. In the past two decades, the diagnosis of pediatric hospital-acquired VTE (HA-VTE) in the U.S. has increased 130-200-fold. The investigators have shown that critically-ill adolescents are one the highest risk subpopulations for HA-VTE, with average occurrence rates of 13.2% (range: 6.3-19.8%), and have derived and prospectively validated risk models for HA-VTE in this population. Despite a simultaneously increased risk of bleeding in critically ill adolescents, particularly after surgery or major trauma, an investigator-initiated multicenter phase 2 trial recently led by the investigators group during the COVID-19 pandemic demonstrated the safety of LMWH for primary HA-VTE prevention. To date, risk-stratified phase 3 Randomized Controlled Trials (RCTs) of LMWH thromboprophylaxis as primary HA-VTE prevention in children have not been performed. The investigators will perform a U.S.-based definitive multicenter phase 3 RCT of the LMWH enoxaparin versus no pharmacological thromboprophylaxis for VTE prevention among critically ill adolescents at highest a priori risk for HA-VTE applying evidence from the investigators published risk prediction models.

03

Conditions studied

  • Venous Thromboembolism (VTE)

Keywords

  • pediatric
  • adolescent
  • critical illness
  • thromboprophylaxis
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission Age between 12- 18 years of age
  • Within 24 hours of pediatric intensive care unit (PICU) admission for enrollment
  • Presence of a Central Venous Catheter
  • Presumed or confirmed infection or systemic inflammatory condition

Exclusion criteria

Exclusion Criteria:

  • Active treatment for VTE or known VTE present prior to or on pediatric intensive care unit (PICU) admission
  • Current receipt of an antithrombotic agent excluding unfractionated heparin for vascular catheter patency
  • Active ISTH-defined bleeding
  • Surgery in the last 7-days
  • Major trauma within the last 7-days
  • Admission for management of congenital heart disease including perioperative management of critical congenital heart disease
  • Presence of coagulopathy including:
  • (INR) 2.0 activated partial thromboplastin time (aPTT) 50 seconds count 50 x103/mL
  • 30 ml/min/1.73 m2
  • Known to heparin or pork products
  • Laboratory confirmed heparin induced thrombocytopenia
  • Current pregnancy or lactation,
  • Presence of an epidural catheter
  • Prior enrollment in the CRITICAL-Teens-TP Trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
802 participants (estimated)

Study arms

  • Experimental
    EnoxaparinThromboprophylaxis

    This arm will receive the study intervention, enoxaparin thromboprophylaxis during pediatric intensive care unit hospitalization

    Drug: Enoxaparin

  • No intervention
    No Pharmacological Thromboprophylaxis

    This arm will receive no pharmacological thromboprophylaxis

Interventions

  • Enoxaparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge

06

What researchers measure

Primary outcomes

  1. Risk (i.e., cumulative incidence) of Symptomatic venous thromboembolism

    International Society on Thrombosis and Haemostasis (ISTH) defined symptomatic venous thromboembolism

    Time frame: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks

  2. Risk (i.e., cumulative incidence) of Clinically relevant bleeding

    International Society on Thrombosis and Haemostasis (ISTH) defined clinically relevant bleeding (Major bleeding + Clinically relevant Non-major bleeding)

    Time frame: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks

Secondary outcomes

  1. Net Clinical Benefit - Modelled Attributable Risk Difference in HA-VTE (Efficacy) by Attributable Risk Difference in clinically relevant bleeding (Safety)

    Net clinical benefit is a bivariate endpoint analysis (i.e., trade-off of venous thromboembolism and bleeding risks as described below). One-year risks and corresponding 95% confidence intervals (CI) of hospital-acquired venous thromboembolism and clinically relevant bleeding for each study arm will be calculated from weighted Kaplan-Meier curves. A bivariate decision curve will be specified using the 12-month absolute risk difference for venous thromboembolism and bleeding outcomes. Bivariate outcomes for enoxaparin and no pharmacological thromboprophylaxis will be compared under a hypothesis of superiority using the superiority boundary of a bivariate endpoint analysis, with inference based on the 95% confidence rectangle (i.e., the rectangle defined by the 95% CI for hospital-acquired venous thromboembolism absolute risk difference and the 95% CI for bleeding absolute risk difference). Superiority will be decided if the 95% confidence rectangle rules out the superiority curve.

    Time frame: From randomization through discharge from the pediatric intensive care unit, approximately 1-2 weeks

  2. Risk (i.e. cumulative incidence) of symptomatic venous thromboembolism

    International Society on Thrombosis and Haemostasis-defined symptomatic venous thromboembolism

    Time frame: From randomization through 30-days post discharge from the pediatric intensive care unit

  3. Risk (i.e. cumulative incidence) of clinically relevant bleeding

    International Society on Thrombosis and Haemostasis-defined clinically relevant bleeding (Major Bleeding + Clinically Relevant Non-Major Bleeding)

    Time frame: From randomization through 30-days post discharge from the pediatric intensive care unit

  4. Serious adverse events

    As federally defined.

    Time frame: From randomization through 30-days post discharge from the pediatric intensive care unit

07

Study locations

1 site
08

References and documents

Publications

  • Sochet AA, Amankwah EK, Andalib V, Jaffray J, Male C, Faustino EV, Goldenberg NA; Pedi-ATLAS Group and the Antithrombotic Trials Working Party of the Pediatric Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Enhanced trial efficiency of the novel "contemporaneous control recapture" parallel-cohort RCT design: Methods and application in the CRITICAL-Kids-TP trial. Contemp Clin Trials. 2026 Jan;160:108142. doi: 10.1016/j.cct.2025.108142. Epub 2025 Nov 10. PubMed 41223938 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Apr 2034, 84 months later.

Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 84 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 8, 2024
StartEst.
Apr 15, 2027
Primary completionEst.
Apr 15, 2034
CompletionEst.
Apr 15, 2035
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06628778
Lead sponsor
Johns Hopkins All Children's Hospital
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Apr 15, 2027 (estimated)
Primary completion
Apr 15, 2034 (estimated)
Completion
Apr 15, 2035 (estimated)
Last update
May 26, 2026

Study contacts

Anthony A Sochet, MD, MSc
Contact
sochet@jhmi.edu
727-767-2912
Neil A Goldenberg, MD, Phd
Contact
neil@jhmi.edu
727-767-2912
Anthony Sochet, MD, MSc
principal investigator · Johns Hopkins All Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion